RxDoctor Payments Data

Amelia Brown

Psychiatric/Mental Health · Jacksonville, FLNPI 1316297054

Payments from drug & device makers

$4,840in general payments, 2019–2025

Across 151 payments — averaging $32.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$575
  • Otsuka America Pharmaceutical, Inc.$467
  • Teva Pharmaceuticals USA, Inc.$237
  • Axsome Therapeutics, Inc.$213
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$4,840100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,840 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$72,696
Medicare patients
101
Services billed
624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine24$214,934
SpravatoEsketamine Hcl69$84,321
VraylarCariprazine Hcl29$58,548
Invega SustennaPaliperidone Palmitate16$51,026
CaplytaLumateperone Tosylate23$41,573
RexultiBrexpiprazole16$30,529
Vilazodone Hcl53$7,617
Duloxetine Hcl146$4,221
Lurasidone Hcl30$3,264
Quetiapine Fumarate ErQuetiapine Fumarate41$2,560
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine51$2,394
Oxcarbazepine24$2,082
Fluvoxamine Maleate30$1,816
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine42$1,703
Clonazepam157$1,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$237$214,93424 claims
Johnson & JohnsonSpravato, Invega Sustenna$1,044$135,34785 claims
AbbVieVraylar$1,270$58,54829 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$575$41,57323 claims
Otsuka America Pharmaceutical, Inc.Rexulti$467$30,52916 claims
Almatica Pharma LLCSertraline Hcl$39$46639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →